BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 1991174)

  • 1. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.
    Jones RJ; Ambinder RF; Piantadosi S; Santos GW
    Blood; 1991 Feb; 77(3):649-53. PubMed ID: 1991174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.
    Ratanatharathorn V; Uberti J; Karanes C; Abella E; Lum LG; Momin F; Cummings G; Sensenbrenner LL
    Blood; 1994 Aug; 84(4):1050-5. PubMed ID: 8049425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
    Verdonck LF; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK
    Blood; 1997 Nov; 90(10):4201-5. PubMed ID: 9354692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.
    Akpek G; Ambinder RF; Piantadosi S; Abrams RA; Brodsky RA; Vogelsang GB; Zahurak ML; Fuller D; Miller CB; Noga SJ; Fuchs E; Flinn IW; O'Donnell P; Seifter EJ; Mann RB; Jones RJ
    J Clin Oncol; 2001 Dec; 19(23):4314-21. PubMed ID: 11731514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.
    Jones RJ; Piantadosi S; Mann RB; Ambinder RF; Seifter EJ; Vriesendorp HM; Abeloff MD; Burns WH; May WS; Rowley SD
    J Clin Oncol; 1990 Mar; 8(3):527-37. PubMed ID: 2307990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children.
    Parsons SK; Castellino SM; Lehmann LE; Eickhoff CE; Tarbell NJ; Sallan SE; Weinstein HJ; Billett AL
    Bone Marrow Transplant; 1996 May; 17(5):763-8. PubMed ID: 8733695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.
    Holmqvist AS; Chen Y; Wu J; Battles K; Bhatia R; Francisco L; Hageman L; Kung M; Ness E; Parman M; Salzman D; Wadhwa A; Winther JF; Rosenthal J; Forman SJ; Weisdorf DJ; Armenian SH; Arora M; Bhatia S
    JAMA Oncol; 2018 Dec; 4(12):e182453. PubMed ID: 30054602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
    Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
    Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New conditioning regimens for high risk marrow transplants.
    Jones RJ; Santos GW
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma.
    Shepherd JD; Barnett MJ; Connors JM; Spinelli JJ; Sutherland HJ; Kingemann HG; Nantel SH; Reece DE; Currie CJ; Phillips GL
    Bone Marrow Transplant; 1993 Dec; 12(6):591-6. PubMed ID: 8136743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M; van Besien KW; Giralt SA; Khouri IF; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Korbling M; Champlin RE
    Bone Marrow Transplant; 1997 Jan; 19(2):121-7. PubMed ID: 9116608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.
    Phillips GL; Barnett MJ; Brain MC; Chan KW; Huebsch LB; Klingemann HG; Meharchand J; Reece DE; Rybka WB; Shepherd JD
    Bone Marrow Transplant; 1991 Dec; 8(6):477-87. PubMed ID: 1790428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience.
    Nachbaur D; Oberaigner W; Fritsch E; Nussbaumer W; Gastl G
    Eur J Haematol; 2001 Jan; 66(1):43-9. PubMed ID: 11168507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
    Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
    Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.